Trial Profile
A Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms NEFERTT
- Sponsors Puma Biotechnology; Wyeth Pharmaceuticals
- 14 Dec 2019 Primary endpoint has not been met. (Progression-Free Survival)
- 14 Dec 2019 Results of pooled analysis from the NALA, NEfERT-T, and TBCRC 022 trials, assessing Impact of neratinib on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 08 Feb 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.